CD274 and neoplasm: Some failures to neoantigen vaccines are attributed to immune inhibitory tumor microenvironment—partly contributed by up regulation of PD-L1 due to the vaccine’s effects—which can be overcome by combining neoantigen vaccine with immune checkpoint inhibitor therapy [47, 48].